Sarcomatous Component in Pancreatic Adenosquamous Carcinoma: A Clinicopathological Series of 7 Cases

Taniwaki, S; Hisaka, Toru; Sakai, Hisamune; Goto, Yuichi; Nomura, Yoshio; Kawahara, Ryuichi; Ishikawa, Hiroto; Yasunaga, Masafumi; Naito, Yoshiki; Akiba, Jun; Yano, Hirohisa; Tanaka, Hiroyuki; Akagi, Yoshito; Okuda, K

doi:10.21873/anticanres.13636

Cited by 5 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This type of dual staining was also seen in some PDAC samples that lacked any histologic squamous component. Recently, a retrospective study identified a sarcomatous component to ASCP in 7 of 7 cases [ 54 ] , but this finding has not been mentioned by others except for one case report describing a particularly large ASCP [ 56 ] . Immunologically, the adenocarcinoma component of ASCP resembles PDAC; however, ASCP has been noted to frequently express PD-L1 within the squamous component [ 57 , 58 ] .…”

Section: Adenosquamous Carcinoma Of the Pancreas (Ascp)mentioning

confidence: 99%

Two rare cancers of the exocrine pancreas: to treat or not to treat like ductal adenocarcinoma?

2023

J Cancer Metastasis Treat

View full text Add to dashboard Cite

Pancreatic cancer is an aggressive malignancy with increasing incidence. Pancreatic ductal adenocarcinoma (PDAC) accounts for > 90% of pancreatic cancer diagnoses, while other exocrine tumors are much rarer. In this review, we have focused on two rare cancers of the exocrine pancreas: adenosquamous carcinoma of the pancreas (ASCP) and pancreatic acinar cell carcinoma (PACC). The latest findings regarding their cellular and molecular pathology, clinical characteristics, prognosis, and clinical management are discussed. New genetic and transcriptomic data suggest that ASCP is related to or overlaps with the basal transcriptomic subtype of PDAC. These tumors are highly aggressive and driven by activated KRAS and MYC expression. Clinical outcomes remain poor and effective treatments are limited. PACC has no morphologic or genetic resemblance to PDAC and more favorable outcomes. Early stage PACC patients have improved survival with surgical resection and patients with advanced disease benefit most from platinum-or fluoropyrimidine-containing chemotherapy. Frequency of actionable genetic mutations is high in this disease and case reports suggest good outcomes when matched therapy is given. Dedicated clinical studies examining ASCP and PACC are limited and difficult to accrue. Further research is needed to define optimal clinical management for these rare diseases.

show abstract